Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction [4]

Thrombosis and Haemostasis

Volumn 94, Issue 4, 2005, Pages 889-891

  von Pape, Klaus Werner ^a   Strupp, Gerhard ^a   Bonzel, Tassilo ^a   Bohner, Jürgen ^a  

^a KLINIKUM FULDA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; HEART INFARCTION; HEMATOCRIT; HUMAN; HUMAN CELL; LETTER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 27144482754     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-04-0889     Document Type: Letter

References (16)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
2. Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group. Br Med J 1998; 316: 1303-9.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
4. Fitzgerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003; 361: 542-4.
5. Bohner J, von Pape K-W, Wiebersinsky W et al. Serial assesment of platelet function following a single 300 mg dose of acetyl salicylic acid. Ann Hematol 1997; 74, suppl II, A136.
6. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
7. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-3.
8. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 5: 156-63.
9. Grotemeyer K, Scharafinski H, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
10. Bach R, Jung F, Kohsiek I et al. Factors affecting the restenosis rate after PTCA. Thromb Res 1994; 74: 55-67.
11. von Pape K-W, Aland E, Bohner J. Platelet function analysis with PEA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 2000; 98: 295-9.
12. Kundu SK, Heilmann EJ, Sio R et al. Description of an in vitro platelet function analyzer-PFA-100. Semin Thromb Haemost 1995; 21 (Suppl 2): 106-12.
13. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Haemost 1995; 21 (Suppl 2): 113-21.
14. Pulcinelli FM, Pignatelli P, Celestini A et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43: 979-84.
15. Cerletti C, Dell'Elba G, Manarini S et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003; 42: 1059-70.
16. Weber AA, Przytulski B, Schanz A et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 37-40.